Mount Yale Investment Advisors LLC acquired a new position in shares of CIGNA Co. (NYSE:CI) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,833 shares of the health services provider’s stock, valued at approximately $475,000.
A number of other institutional investors also recently made changes to their positions in CI. Amalgamated Bank increased its stake in CIGNA by 8.3% during the first quarter. Amalgamated Bank now owns 34,102 shares of the health services provider’s stock worth $5,720,000 after acquiring an additional 2,614 shares during the last quarter. Gyroscope Capital Management Group LLC acquired a new stake in CIGNA during the first quarter worth $346,000. WINTON GROUP Ltd increased its stake in CIGNA by 15.1% during the first quarter. WINTON GROUP Ltd now owns 136,990 shares of the health services provider’s stock worth $22,979,000 after acquiring an additional 17,930 shares during the last quarter. Levin Capital Strategies L.P. acquired a new stake in CIGNA during the first quarter worth $50,972,000. Finally, CIBC World Markets Inc. increased its stake in CIGNA by 62.0% during the first quarter. CIBC World Markets Inc. now owns 15,528 shares of the health services provider’s stock worth $2,605,000 after acquiring an additional 5,944 shares during the last quarter. Hedge funds and other institutional investors own 87.73% of the company’s stock.
A number of equities research analysts have recently weighed in on CI shares. Goldman Sachs Group raised CIGNA from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $193.00 to $212.00 in a research note on Wednesday, June 6th. Zacks Investment Research raised CIGNA from a “hold” rating to a “buy” rating and set a $197.00 price objective for the company in a research note on Monday, May 28th. Sanford C. Bernstein started coverage on CIGNA in a research note on Tuesday, March 13th. They issued a “market perform” rating and a $194.00 price objective for the company. Credit Suisse Group lifted their price objective on CIGNA from $215.00 to $218.00 and gave the company an “outperform” rating in a research note on Friday, May 4th. Finally, Barclays started coverage on CIGNA in a research note on Thursday, March 8th. They issued an “overweight” rating and a $235.00 price objective for the company. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $217.00.
CIGNA opened at $172.81 on Thursday, according to Marketbeat Ratings. CIGNA Co. has a 12 month low of $163.02 and a 12 month high of $227.13. The firm has a market cap of $42.07 billion, a P/E ratio of 14.67, a P/E/G ratio of 1.08 and a beta of 0.58. The company has a quick ratio of 0.35, a current ratio of 0.35 and a debt-to-equity ratio of 0.37.
CIGNA (NYSE:CI) last released its earnings results on Thursday, May 3rd. The health services provider reported $4.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.39 by $0.72. CIGNA had a return on equity of 20.90% and a net margin of 5.99%. The firm had revenue of $11.38 billion during the quarter, compared to analysts’ expectations of $10.97 billion. During the same period in the previous year, the firm posted $2.77 EPS. CIGNA’s revenue for the quarter was up 8.6% on a year-over-year basis. research analysts forecast that CIGNA Co. will post 13.24 EPS for the current fiscal year.
In related news, VP Hoeltzel Mary T. Agoglia sold 1,000 shares of the business’s stock in a transaction on Friday, May 25th. The stock was sold at an average price of $176.19, for a total transaction of $176,190.00. Following the completion of the transaction, the vice president now directly owns 4,635 shares of the company’s stock, valued at approximately $816,640.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William D. Zollars sold 265 shares of the business’s stock in a transaction on Thursday, June 14th. The stock was sold at an average price of $176.93, for a total value of $46,886.45. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.
CIGNA Company Profile
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.